International Journal of Stem Cells : eISSN 2005-5447

Table. 2.

Table. 2.

Clinical trials on stem cell therapy in liver disease

Source of stem cells No. of patients Year Reference
1 BM-MNCs 9 2006 (59)
2 PB-MNCs, G-CSF 2 2006 (60)
3 BM-MSCs, G-CSF Active Treatment: 8 (5 male) 2006 (61)
4 CD34+ cells 5 2006 (62)
5 CD34+ cells 4 2007 (63)
6 BM-MSCs 10 2007 (64)
7 PB-monocytes, G-CSF 2 2007 (65)
8 CD34+ cells 4 2008 (66)
9 CD34+ cells 5 2008 (67)
10 PB-MSCs, G-CSF 40 2008 (68)
11 CD34+ cells 9 2008 (69)
12 CD34+, CD133+ HSCs Active Treatment: 90 (78 male) 2010 (70)
13 BM-MNCs 10 2010 (71)
14 BM-MNCs 15 2010 (72)
15 hHPCs Active Treatment: 4 2010 (73)
16 BM-MNCs, HSCs 6 2011 (74)
17 BM-MNCs 5 2011 (75)
18 BM-MNCs (BM-derived hepatocytes) 20 2011 (76)
19 CD34+ cells, G-CSF 23 2012 (77)
20 BM-MSCs, G-CSF 28 2013 (78)
21 BM CD133+ cells 16 2015 (79)
22 BM CD134+ cells, G-CSF 81 2015 (80)
23 PB CD34+ cells 22 2015 (81)
24 BM CD133+ cells, MNCs 12 2016 (82)
25 PB monocytes 9 2017 (83)

Source of stem cells Clinicaltrials.gov identifier Year Phase

26 Autologous expanded CD34+ HSCs NCT00655707 2008∼2015 Phase2
27 Autologous BM cells NCT02943707 2016∼2020 Phase2
28 Autologous BM-derived CD133 stem cells NCT01120925 2010∼2014 Phase2
29 BM cells NCT01412593 2011∼2013 Phase2
30 Autologous BM-derived CD133 stem cells NCT00713934 2008∼2010 Phase1
31 Adult stem cells NCT00147034 2005∼2016 Phase1
32 Autologous BM-derived CD133 stem cells NCT01025622 2009∼2010 Phase1
33 Allogenic BMSCs NCT01221454 2010 Phase2
34 Allogenic BMSCs NCT01223664 2010 Phase2
35 Human BMSCs NCT01724697 2012 Phase1
36 Autologous BMSCs NCT02943707 2016 Phase2
International Journal of Stem Cells 2020;13:1-12 https://doi.org/10.15283/ijsc19127
© 2019 International Journal of Stem Cells